Caris Life Sciences, INC 8-K filings

Caris Life Sciences announced a 45% revenue increase in Q2 2026, driven by molecular profiling services, and raised its full-year revenue guidance to $1.03-$1.04 billion.

Caris Life Sciences shareholders successfully elected ten directors and ratified the appointment of Deloitte & Touche LLP as the independent auditor for 2026.

Caris Life Sciences has entered into a new $1.2 billion senior secured credit agreement to refinance existing debt and support future acquisitions.

Caris Life Sciences announced robust financial results for Q4 and full year 2025, driven by significant growth in molecular profiling services, and provided an optimistic 2026 revenue outlook of $1.0 billion to $1.02 billion.

Caris Life Sciences announced preliminary unaudited Q4 and full-year 2025 financial results, showcasing significant revenue and case volume growth.

Caris Life Sciences reported record third-quarter 2025 financial results, including a 113.4% revenue increase and positive net income, while raising full-year revenue guidance.

Caris Life Sciences, Inc. has amended its bylaws, requiring shareholders to beneficially own at least 3% of outstanding shares to initiate or maintain a derivative proceeding.

Caris Life Sciences reported strong second quarter 2025 financial results, with total revenue increasing by 81.3% and achieving positive Adjusted EBITDA and cash flow from operations.

Caris Life Sciences, Inc. successfully completed its initial public offering, raising $494.1 million in gross proceeds, and concurrently enacted its Amended and Restated Certificate of Formation and Bylaws to align with its new public company status.